Advertisement

Tumor Biology

, Volume 36, Issue 9, pp 7133–7142 | Cite as

JARID1B modulates lung cancer cell proliferation and invasion by regulating p53 expression

  • Xudong Shen
  • Zhixiang Zhuang
  • Yusong Zhang
  • Zhigang Chen
  • Liqin Shen
  • Wangyang Pu
  • Lei Chen
  • Zhonghua Xu
Research Article

Abstract

Although three therapeutic modalities (surgical resection, chemotherapy, and radiotherapy) have been established, long-term survival for lung cancer patients is still generally poor. Until now, the mechanisms of lung cancer genesis remain elusive. The JARID1B is a histone demethylase that has been proposed as oncogene in several types of human cancer, but its clinical significance and functional role in human non-small cell lung cancer (NSCLC) remain unclear. In present study, we found that JARID1B was overexpressed in lung cancer cell lines and lung cancer tissues but not in normal lung tissues. The proliferation and invasive potential of lung cancer cells was significantly increased by ectopic expression of JARID1B. Contrarily, RNA interference targeting JARID1B in lung cancer cells significantly decreased the proliferation and invasive potential of cells. Moreover, we also found that the expression of p53 was modulated by JARID1B. Overexpressed JARID1B cell exhibited greatly decreased p53 expression, whereas silencing of JARID1B expression dramatically increased p53 expression at both the messenger RNA (mRNA) and protein levels. Inhibition of p53 by small interfering RNA (siRNA) reversed the shJARID1B-induced suppression of proliferation and invasion. Our results collectively suggested that JARID1B expressed in lung cancer played a role in lung cancer cells proliferation and invasion, which may be partly associated with the p53 expression.

Keywords

JARID1B Lung cancer p53 Proliferation Invasion 

Notes

Acknowledgments

This project was supported by National Natural Science Foundation of China (81171488).

Conflicts of interest

None

Supplementary material

13277_2015_3418_MOESM1_ESM.jpg (960 kb)
The effects of JARID1B on the p53 and p21 mRNA expression. A: The expression of p53 and p27 in JARID1B-transfected H1299 cells and its control cells were examined using qRT-PCR. B: The expression of p53 and p27 in JARID1B knockdown A549 cells and its control cells were examined using qRT-PCR. (JPEG 961 KB)

References

  1. 1.
    Nana-Sinkam SP, Powell CA. Molecular biology of lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e30S–9.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Berge EM, Doebele RC. Targeted therapies in non-small cell lung cancer: emerging oncogene targets following the success of epidermal growth factor receptor. Semin Oncol. 2014;41(1):110–25.CrossRefPubMedGoogle Scholar
  3. 3.
    Reungwetwattana T, Dy GK. Targeted therapies in development for non-small cell lung cancer. J Carcinog. 2013;12:22.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Berry WL, Janknecht R. KDM4/JMJD2 histone demethylases: epigenetic regulators in cancer cells. Cancer Res. 2013;73(10):2936–42.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Marmorstein R, Trievel RC. Histone modifying enzymes: structures, mechanisms, and specificities. Biochim Biophys Acta. 2009;1789(1):58–68.CrossRefPubMedGoogle Scholar
  6. 6.
    Young LC, Hendzel MJ. The oncogenic potential of Jumonji D2 (JMJD2/KDM4) histone demethylase overexpression. Biochem Cell Biol = Biochimie et biologie cellulaire. 2013;91(6):369–77.CrossRefPubMedGoogle Scholar
  7. 7.
    Berry WL, Kim TD, Janknecht R. Stimulation of beta-catenin and colon cancer cell growth by the KDM4B histone demethylase. Int J Oncol. 2014;44(4):1341–8.PubMedGoogle Scholar
  8. 8.
    Chen L, Fu L, Kong X, Xu J, Wang Z, Ma X, et al. Jumonji domain-containing protein 2B silencing induces DNA damage response via STAT3 pathway in colorectal cancer. Br J Cancer. 2014;110(4):1014–26.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Antony J, Oback F, Chamley LW, Oback B, Laible G. Transient JMJD2B-mediated reduction of H3K9me3 levels improves reprogramming of embryonic stem cells into cloned embryos. Mol Cell Biol. 2013;33(5):974–83.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Coffey K, Rogerson L, Ryan-Munden C, Alkharaif D, Stockley J, Heer R, et al. The lysine demethylase, KDM4B, is a key molecule in androgen receptor signalling and turnover. Nucleic Acids Res. 2013;41(8):4433–46.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Yang J, Jubb AM, Pike L, Buffa FM, Turley H, Baban D, et al. The histone demethylase JMJD2B is regulated by estrogen receptor alpha and hypoxia, and is a key mediator of estrogen induced growth. Cancer Res. 2010;70(16):6456–66.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Toyokawa G, Cho HS, Iwai Y, Yoshimatsu M, Takawa M, Hayami S, et al. The histone demethylase JMJD2B plays an essential role in human carcinogenesis through positive regulation of cyclin-dependent kinase 6. Cancer Prev Res (Philadelphia, Pa). 2011;4(12):2051–61.CrossRefGoogle Scholar
  13. 13.
    Fu L, Chen L, Yang J, Ye T, Chen Y, Fang J. HIF-1alpha-induced histone demethylase JMJD2B contributes to the malignant phenotype of colorectal cancer cells via an epigenetic mechanism. Carcinogenesis. 2012;33(9):1664–73.CrossRefPubMedGoogle Scholar
  14. 14.
    Wang Y, Wen M, Kwon Y, Xu Y, Liu Y, Zhang P, et al. CUL4A induces epithelial-mesenchymal transition and promotes cancer metastasis by regulating ZEB1 expression. Cancer Res. 2014;74(2):520–31.CrossRefPubMedGoogle Scholar
  15. 15.
    Qiao Q, Hu W. The association between TP53 Arg72Pro polymorphism and lung cancer susceptibility: evidence from 30,038 subjects. Lung. 2013;191(4):369–77.CrossRefPubMedGoogle Scholar
  16. 16.
    Zhang B, Wang E, Dai H, Hu R, Liang Y, Li K, et al. BRIT1 regulates p53 stability and functions as a tumor suppressor in breast cancer. Carcinogenesis. 2013;34(10):2271–80.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Fodor BD, Kubicek S, Yonezawa M, O’Sullivan RJ, Sengupta R, Perez-Burgos L, et al. Jmjd2b antagonizes H3K9 trimethylation at pericentric heterochromatin in mammalian cells. Genes Dev. 2006;20(12):1557–62.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Kawazu M, Saso K, Tong KI, McQuire T, Goto K, Son DO, et al. Histone demethylase JMJD2B functions as a co-factor of estrogen receptor in breast cancer proliferation and mammary gland development. PLoS One. 2011;6(3).Google Scholar
  19. 19.
    Shi Y, Whetstine JR. Dynamic regulation of histone lysine methylation by demethylases. Mol Cell. 2007;25(1):1–14.CrossRefPubMedGoogle Scholar
  20. 20.
    Xu Y, Wang Y, Ma G, Wang Q, Wei G. CUL4A is overexpressed in human pituitary adenomas and regulates pituitary tumor cell proliferation. J Neuro-Oncol. 2014;116(3):625–32.CrossRefGoogle Scholar
  21. 21.
    Wang Q, Wang Y, Zhang Y, Zhang Y, Xiao W. The role of uPAR in epithelial-mesenchymal transition in small airway epithelium of patients with chronic obstructive pulmonary disease. Respir Res. 2013;14:67.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Yang P, Du CW, Kwan M, Liang SX, Zhang GJ. The impact of p53 in predicting clinical outcome of breast cancer patients with visceral metastasis. Sci Rep. 2013;3:2246.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Wang Y, Ma G, Wang Q, Wen M, Xu Y, He X, et al. Involvement of CUL4A in regulation of multidrug resistance to P-gp substrate drugs in breast cancer cells. Molecules. 2013;19(1):159–76.CrossRefPubMedGoogle Scholar
  24. 24.
    Shapira I, Lee A, Vora R, Budman DR. P53 mutations in triple negative breast cancer upregulate endosomal recycling of epidermal growth factor receptor (EGFR) increasing its oncogenic potency. Crit Rev Oncol/Hematol. 2013;88(2):284–92.CrossRefGoogle Scholar
  25. 25.
    Rieber M, Strasberg-Rieber M. p53 inactivation decreases dependence on estrogen/ERK signalling for proliferation but promotes EMT and susceptibility to 3-bromopyruvate in ERalpha + breast cancer MCF-7 cells. Biochem Pharmacol. 2014;88(2):169–77.CrossRefPubMedGoogle Scholar
  26. 26.
    Chicas A, Kapoor A, Wang X, Aksoy O, Evertts AG, Zhang MQ, et al. H3K4 demethylation by Jarid1a and Jarid1b contributes to retinoblastoma-mediated gene silencing during cellular senescence. Proc Natl Acad Sci U S A. 2012;109(23):8971–6.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Albert M, Schmitz SU, Kooistra SM, Malatesta M, Morales Torres C, Rekling JC, et al. The histone demethylase Jarid1b ensures faithful mouse development by protecting developmental genes from aberrant H3K4me3. PLoS Genet. 2013;9(4):e1003461.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Xudong Shen
    • 1
  • Zhixiang Zhuang
    • 1
  • Yusong Zhang
    • 1
  • Zhigang Chen
    • 1
  • Liqin Shen
    • 1
  • Wangyang Pu
    • 1
  • Lei Chen
    • 1
  • Zhonghua Xu
    • 2
  1. 1.Department of OncologyThe Second Affiliated Hospital of Soochow UniversitySuzhouChina
  2. 2.Department of Thoracic SurgeryThe Second Affiliated Hospital of Soochow UniversitySuzhouChina

Personalised recommendations